In this issue:
Ustekinumab for severe psoriatic arthritis
Vitamin D: diseasemodifying benefits in SLE?
Pegloticase promising in refractory gout
Adalimumab can be stopped in low-activity RA
Active RA after MTX failure
MTX-first valid in early poor-prognosis RA
Long-term safety of rituximab in RA
Examining the risk of serious infection in RA
NSAIDs and COX-2 inhibitors: vascular risks defined
TNF-α blockade: CV benefit in RA?
Please login below to download this issue (PDF)